Handelen Adverum Biotechn - ADVM CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.0190 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Adverum Biotechnologies Inc ESG Risk Ratings
High Medium Low Negligible
‘B’ score indicates good relative ESG performance and above average degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 1.4754 |
| Open* | 1.4454 |
| 1-Jaarlijkse Verandering* | 35.08% |
| Dagelijks bereik* | 1.4454 - 1.5552 |
| 52 wekelijks bereik | 0.53-1.82 |
| Weekgemiddelde volume (10 dagen) | 436.90K |
| Gemiddeld volume (3 maanden) | 8.81M |
| Marktkapitalisatie | 140.81M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 100.58M |
| Omzet | 3.60M |
| EPS | -1.46 |
| Dividend (opbrengst %) | N/A |
| Beta | 0.72 |
| Volgende inkomsten datum | Aug 9, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Jun 7, 2023 | 1.4754 | 0.0897 | 6.47% | 1.3857 | 1.5053 | 1.3258 |
| Jun 6, 2023 | 1.4056 | 0.1097 | 8.47% | 1.2959 | 1.4056 | 1.2959 |
| Jun 5, 2023 | 1.3458 | 0.1895 | 16.39% | 1.1563 | 1.3458 | 1.1064 |
| Jun 2, 2023 | 1.1763 | 0.0399 | 3.51% | 1.1364 | 1.2162 | 1.1364 |
| Jun 1, 2023 | 1.1364 | -0.0897 | -7.32% | 1.2261 | 1.2261 | 1.1164 |
| May 31, 2023 | 1.1962 | 0.0797 | 7.14% | 1.1165 | 1.2062 | 1.0965 |
| May 30, 2023 | 1.1165 | 0.1695 | 17.90% | 0.9470 | 1.1165 | 0.9469 |
| May 26, 2023 | 0.9470 | -0.0099 | -1.03% | 0.9569 | 0.9769 | 0.9270 |
| May 25, 2023 | 0.9470 | 0.0896 | 10.45% | 0.8574 | 0.9968 | 0.8572 |
| May 24, 2023 | 0.8612 | -0.0359 | -4.00% | 0.8971 | 0.8971 | 0.8581 |
| May 23, 2023 | 0.9063 | 0.0291 | 3.32% | 0.8772 | 0.9684 | 0.8772 |
| May 22, 2023 | 0.8829 | 0.0755 | 9.35% | 0.8074 | 0.8870 | 0.8074 |
| May 19, 2023 | 0.7974 | 0.0498 | 6.66% | 0.7476 | 0.8225 | 0.7316 |
| May 18, 2023 | 0.7562 | -0.0213 | -2.74% | 0.7775 | 0.7791 | 0.7476 |
| May 17, 2023 | 0.7675 | -0.0299 | -3.75% | 0.7974 | 0.8074 | 0.7675 |
| May 16, 2023 | 0.7974 | -0.0100 | -1.24% | 0.8074 | 0.8174 | 0.7974 |
| May 15, 2023 | 0.8184 | 0.0110 | 1.36% | 0.8074 | 0.8290 | 0.7974 |
| May 12, 2023 | 0.8074 | 0.0050 | 0.62% | 0.8024 | 0.8174 | 0.7815 |
| May 11, 2023 | 0.8189 | -0.0034 | -0.41% | 0.8223 | 0.8273 | 0.7990 |
| May 10, 2023 | 0.8307 | 0.0333 | 4.18% | 0.7974 | 0.8409 | 0.7974 |
Adverum Biotechn Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Friday, June 9, 2023 | ||
| Tijd (UTC) (UTC) 14:00 | Land US
| Evenement Adverum Biotechnologies Inc at Jefferies Healthcare Conference Adverum Biotechnologies Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Tijd (UTC) (UTC) 15:00 | Land US
| Evenement Adverum Biotechnologies Inc Annual Shareholders Meeting Adverum Biotechnologies Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 9, 2023 | ||
| Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q2 2023 Adverum Biotechnologies Inc Earnings Release Q2 2023 Adverum Biotechnologies Inc Earnings ReleaseForecast -Previous - |
| Wednesday, November 8, 2023 | ||
| Tijd (UTC) (UTC) 21:05 | Land US
| Evenement Q3 2023 Adverum Biotechnologies Inc Earnings Release Q3 2023 Adverum Biotechnologies Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 0 | 7.5 | 0 | 0.25 | 1.612 |
| Inkomsten | 0 | 7.5 | 0 | 0.25 | 1.612 |
| Totale bedrijfskosten | 157.135 | 153.622 | 117.95 | 68.795 | 79.693 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 55.758 | 63.341 | 44.641 | 28.376 | 24.56 |
| Onderzoek & Ontwikkeling | 99.277 | 89.181 | 73.309 | 40.419 | 50.133 |
| Ongebruikelijke uitgaven (inkomsten) | 2.1 | 1.1 | 0 | 5 | |
| Bedrijfsresultaat | -157.135 | -146.122 | -117.95 | -68.545 | -78.081 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | |||||
| Overige, Netto | 2.673 | 0.582 | 1.557 | 4.059 | 4.204 |
| Netto inkomen voor belastingen | -154.462 | -145.54 | -116.393 | -64.486 | -73.877 |
| Netto inkomen na belastingen | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Netto inkomen voor extra. Posten | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Netto inkomen | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Verwaterd Netto Inkomen | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Verwaterd Gewogen Gemiddelde Aandelen | 99.251 | 98.039 | 85.146 | 64.102 | 61.375 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -1.55702 | -1.48451 | -1.38006 | -1.00599 | -1.18333 |
| Verwaterde Genormaliseerde Winst per Aandeel | -1.54327 | -1.47329 | -1.38006 | -1.00599 | -1.13038 |
| Totale buitengewone posten |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 3.6 | 0 | 0 | 0 | 0 |
| Inkomsten | 3.6 | 0 | 0 | 0 | 0 |
| Totale bedrijfskosten | 33.839 | 33.94 | 41.037 | 44.025 | 38.133 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 12.78 | 9.641 | 17.188 | 13.76 | 15.169 |
| Onderzoek & Ontwikkeling | 21.059 | 22.199 | 23.849 | 28.265 | 22.964 |
| Bedrijfsresultaat | -30.239 | -33.94 | -41.037 | -44.025 | -38.133 |
| Overige, Netto | 1.2 | 1.223 | 0.923 | 0.283 | 0.244 |
| Netto inkomen voor belastingen | -29.039 | -32.717 | -40.114 | -43.742 | -37.889 |
| Netto inkomen na belastingen | -29.056 | -32.736 | -40.131 | -43.761 | -37.908 |
| Netto inkomen voor extra. Posten | -29.056 | -32.736 | -40.131 | -43.761 | -37.908 |
| Netto inkomen | -29.056 | -32.736 | -40.131 | -43.761 | -37.908 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -29.056 | -32.736 | -40.131 | -43.761 | -37.908 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -29.056 | -32.736 | -40.131 | -43.761 | -37.908 |
| Verwaterd Netto Inkomen | -29.056 | -32.736 | -40.131 | -43.761 | -37.908 |
| Verwaterd Gewogen Gemiddelde Aandelen | 100.304 | 99.923 | 99.475 | 99 | 98.596 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.28968 | -0.32761 | -0.40343 | -0.44203 | -0.38448 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.28968 | -0.31395 | -0.40343 | -0.4289 | -0.38448 |
| Ongebruikelijke uitgaven (inkomsten) | 2.1 | 0 | 2 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 190.595 | 317.145 | 434.438 | 175.87 | 208.754 |
| Geldmiddelen en kortetermijnbeleggingen | 185.589 | 305.188 | 429.729 | 166.035 | 205.079 |
| Geldmiddelen & Equivalenten | 68.431 | 34.195 | 62.424 | 65.897 | 154.949 |
| Totale Vorderingen, Netto | 0 | 5.709 | |||
| Prepaid Expenses | 5.006 | 6.248 | 4.709 | 9.835 | 3.675 |
| Total Assets | 308.372 | 439.727 | 482.567 | 222.727 | 213.495 |
| Property/Plant/Equipment, Total - Net | 113.861 | 119.06 | 47.101 | 45.847 | 3.586 |
| Property/Plant/Equipment, Total - Gross | 130.855 | 132.234 | 57.173 | 53.839 | 10.008 |
| Accumulated Depreciation, Total | -16.994 | -13.174 | -10.072 | -7.992 | -6.422 |
| Intangibles, Net | 0 | ||||
| Other Long Term Assets, Total | 3.916 | 2.753 | 1.028 | 1.01 | 1.155 |
| Total Current Liabilities | 32.246 | 21.32 | 20.871 | 19.408 | 10.719 |
| Accounts Payable | 2.238 | 1.387 | 2.81 | 4.103 | 1.707 |
| Accrued Expenses | 29.754 | 18.615 | 18.061 | 15.305 | 8.784 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 0.254 | 1.318 | 0.228 | ||
| Total Liabilities | 126.854 | 123.542 | 48.22 | 47.77 | 12.328 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Income Tax | 0 | ||||
| Other Liabilities, Total | 94.608 | 102.222 | 27.349 | 28.362 | 1.609 |
| Total Equity | 181.518 | 316.185 | 434.347 | 174.957 | 201.167 |
| Common Stock | 0.01 | 0.01 | 0.01 | 0.007 | 0.006 |
| Additional Paid-In Capital | 985.651 | 964.965 | 937.134 | 560.704 | 522.503 |
| Retained Earnings (Accumulated Deficit) | -802.612 | -648.076 | -502.536 | -385.029 | -320.543 |
| Other Equity, Total | -1.531 | -0.714 | -0.261 | -0.725 | -0.799 |
| Total Liabilities & Shareholders’ Equity | 308.372 | 439.727 | 482.567 | 222.727 | 213.495 |
| Total Common Shares Outstanding | 100.117 | 98.381 | 97.549 | 67.329 | 62.9655 |
| Korte Termijn Investeringen | 117.158 | 270.993 | 367.305 | 100.138 | 50.13 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | ||
| Note Receivable - Long Term | 0 | 0.769 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 168.873 | 190.595 | 213.243 | 246.031 | 280.117 |
| Geldmiddelen en kortetermijnbeleggingen | 164.285 | 185.589 | 203.264 | 235.841 | 271.055 |
| Geldmiddelen & Equivalenten | 67.552 | 68.431 | 84.43 | 91.87 | 89.652 |
| Korte Termijn Investeringen | 96.733 | 117.158 | 118.834 | 143.971 | 181.403 |
| Prepaid Expenses | 4.588 | 5.006 | 9.979 | 10.19 | 9.062 |
| Total Assets | 275.577 | 308.372 | 332.362 | 374.955 | 407.394 |
| Property/Plant/Equipment, Total - Net | 102.85 | 113.861 | 116.461 | 121.999 | 122.097 |
| Property/Plant/Equipment, Total - Gross | 121.436 | 130.855 | 133.855 | 137.64 | 136.696 |
| Accumulated Depreciation, Total | -18.586 | -16.994 | -17.394 | -15.641 | -14.599 |
| Other Long Term Assets, Total | 3.854 | 3.916 | 2.658 | 2.78 | 2.723 |
| Total Current Liabilities | 46.472 | 32.246 | 28.621 | 30.62 | 23.237 |
| Accounts Payable | 2.863 | 2.238 | 0.846 | 4.698 | 3.245 |
| Accrued Expenses | 43.345 | 29.754 | 27.474 | 25.744 | 18.56 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 117.82 | 126.854 | 124.025 | 130.833 | 124.442 |
| Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Liabilities, Total | 71.348 | 94.608 | 95.404 | 100.213 | 101.205 |
| Total Equity | 157.757 | 181.518 | 208.337 | 244.122 | 282.952 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | |
| Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Additional Paid-In Capital | 990.214 | 985.651 | 980.156 | 975.653 | 970.349 |
| Retained Earnings (Accumulated Deficit) | -831.668 | -802.612 | -769.876 | -729.745 | -685.984 |
| Other Equity, Total | -0.799 | -1.531 | -1.953 | -1.796 | -1.423 |
| Total Liabilities & Shareholders’ Equity | 275.577 | 308.372 | 332.362 | 374.955 | 407.394 |
| Total Common Shares Outstanding | 100.573 | 100.117 | 99.728 | 98.12 | 98.767 |
| Totale Vorderingen, Netto | 0 | 0 | 0 | 0 | |
| Other Current Liabilities, Total | 0.264 | 0.254 | 0.301 | 0.178 | 1.432 |
| Note Receivable - Long Term | 0 | 0 | 4.145 | 2.457 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -154.536 | -145.54 | -117.507 | -64.486 | -72.627 |
| Geldmiddelen uit Operationele Activiteiten | -108.091 | -107.831 | -79.291 | -49.17 | -53.964 |
| Geldmiddelen uit Operationele Activiteiten | 6.528 | 4.645 | 4.158 | 1.573 | 1.75 |
| Niet-Geldelijke Posten | 20.028 | 29.002 | 21.329 | 8.684 | 18.534 |
| Veranderingen in het Operationeel Kapitaal | 19.889 | 4.062 | 12.729 | 5.059 | -0.371 |
| Geldmiddelen uit Investeringsactiviteiten | 141.72 | 78.709 | -280.167 | -68.073 | 69.444 |
| Kapitaaluitgaven | -11.816 | -15.123 | -11.844 | -19.247 | -0.809 |
| Overige Cash Flow investeringsposten, Totaal | 153.536 | 93.832 | -268.323 | -48.826 | 70.253 |
| Geldmiddelen uit Financieringsactiviteiten | 0.607 | 2.397 | 355.985 | 28.191 | 69.949 |
| Financiering van Cash Flow Posten | 0 | -2.043 | -1.47 | -1.191 | |
| Uitgifte (Aflossing) van aandelen, netto | 0.607 | 2.637 | 358.089 | 29.773 | 71.215 |
| Uitgifte (Aflossing) van Schulden, Netto | 0 | -0.24 | -0.061 | -0.112 | -0.075 |
| Wisselkoerseffecten | 0 | ||||
| Nettowijziging in Geldmiddelen | 34.236 | -26.725 | -3.473 | -89.052 | 85.429 |
| Deferred Taxes | 0 | -1.25 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -29.056 | -154.536 | -121.8 | -81.669 | -37.908 |
| Cash From Operating Activities | -22.412 | -108.091 | -89.616 | -57.808 | -28.929 |
| Cash From Operating Activities | 1.592 | 6.528 | 4.816 | 3.028 | 1.425 |
| Non-Cash Items | 3.622 | 20.028 | 15.135 | 12.617 | 5.501 |
| Changes in Working Capital | 1.43 | 19.889 | 12.233 | 8.216 | 2.053 |
| Cash From Investing Activities | 21.533 | 141.72 | 139.486 | 115.118 | 84.383 |
| Capital Expenditures | -0.085 | -11.816 | -11.631 | -10.807 | -4.374 |
| Other Investing Cash Flow Items, Total | 21.618 | 153.536 | 151.117 | 125.925 | 88.757 |
| Cash From Financing Activities | 0 | 0.607 | 0.365 | 0.365 | 0.003 |
| Financing Cash Flow Items | |||||
| Issuance (Retirement) of Stock, Net | 0 | 0.607 | 0.365 | 0.365 | 0.003 |
| Issuance (Retirement) of Debt, Net | 0 | 0 | 0 | 0 | |
| Net Change in Cash | -0.879 | 34.236 | 50.235 | 57.675 | 55.457 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Fidelity Management & Research Company LLC | Investment Advisor | 7.7254 | 7769824 | -3050 | 2023-03-31 | LOW |
| BML Capital Management LLC | Investment Advisor | 7.0268 | 7067179 | 0 | 2023-03-31 | MED |
| Morgan Stanley & Co. LLC | Research Firm | 6.9233 | 6963077 | -170690 | 2023-03-31 | MED |
| Commodore Capital LP | Hedge Fund | 6.1229 | 6158141 | 1158141 | 2023-04-10 | MED |
| BofA Global Research (US) | Research Firm | 5.5598 | 5591790 | -106 | 2023-03-31 | LOW |
| Versant Ventures | Venture Capital | 5.0393 | 5068233 | 0 | 2023-03-31 | LOW |
| Goldman Sachs & Company, Inc. | Research Firm | 4.5316 | 4557659 | 4557659 | 2023-03-31 | MED |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.1194 | 4143131 | 140100 | 2023-03-31 | LOW |
| Sonic GP LLC | Hedge Fund | 1.9886 | 2000000 | -2552068 | 2023-03-31 | |
| Regeneron Pharmaceuticals Inc | Corporation | 1.7988 | 1809098 | 1809098 | 2021-12-31 | |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 1.6571 | 1666601 | -180129 | 2023-03-31 | LOW |
| Newtyn Management, LLC | Hedge Fund | 1.5197 | 1528400 | -106600 | 2023-03-31 | MED |
| Two Sigma Investments, LP | Hedge Fund | 1.2897 | 1297107 | -141240 | 2023-03-31 | HIGH |
| JPMorgan Asset Management U.K. Limited | Investment Advisor/Hedge Fund | 1.2015 | 1208385 | 0 | 2023-03-31 | LOW |
| Renaissance Technologies LLC | Hedge Fund | 1.1302 | 1136741 | 62500 | 2023-03-31 | HIGH |
| AIGH Capital Management, LLC. | Private Equity | 0.8963 | 901440 | 0 | 2023-03-31 | MED |
| GSA Capital Partners LLP | Hedge Fund | 0.8747 | 879684 | 48855 | 2023-03-31 | LOW |
| Assenagon Asset Management S.A. | Investment Advisor | 0.8358 | 840651 | 0 | 2023-03-31 | HIGH |
| Fischer (Laurent D M.D.) | Individual Investor | 0.801 | 805574 | 125433 | 2023-04-01 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 0.7834 | 787900 | 15748 | 2023-03-31 | LOW |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Adverum Biotechn Company profile
Over Adverum Biotechn
Adverum Biotechnologies, Inc. is een gentherapiebedrijf in een klinische fase dat zich richt op oogziekten en zeldzame ziekten. Het ontwikkelt kandidaat-producten voor gentherapie. ADVM-022 is een kandidaat-gentherapieproduct in een klinische fase, ontwikkeld voor de behandeling van natte leeftijdsgebonden maculaire degeneratie (AMD) en diabetisch maculair oedeem (DME). ADVM-022 wordt toegediend als een eenmalige in-office intravitreale (IVT) injectie en is ontworpen om de last van anti-vasculaire endotheliale groeifactor (anti-VEGF) injecties te verminderen, de therapietrouw van patiënten te optimaliseren en de visusresultaten te verbeteren voor patiënten met natte AMD of DME. Het voert de OPTIC-studie uit, die is opgezet als een multi-center, open-label, Fase I, dosis-afhankelijk veiligheidsonderzoek van ADVM-022 bij patiënten met natte AMD, bij wie is aangetoond dat ze reageren op anti-VEGF-behandeling. Het bedrijf voert ook de INFINITY-studie uit, een multicenter, Fase II, gerandomiseerde, dubbel gemaskeerde, actieve, vergelijkende gecontroleerde studie waarbij een enkele IVT-injectie van ADVM-022 bij patiënten met DME wordt geëvalueerd.
| Industry: | Bio Therapeutic Drugs |
100 Cardinal Way
REDWOOD CITY
CALIFORNIA 94063
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen